All In Biotech

Drug Trial Radar · NCT00812513

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

Phase II Study of Efficacy of Recombinant Human Platelet-derived Growth Factor (R-Pdf/Gbb) in Healing Wounds Caused by Third Degree Thermal and Electrical Burns.

Last checked: Nov 20, 2026Latest source record: Jul 20, 2011 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

120

Planned (sponsor's estimate)

Start

Jul 2011

Primary completion

Apr 2012

Study completion Apr 2012

Sponsor

Lead sponsor
American Scitech InternationalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Johnson & Johnson
First posted
Dec 22, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Platelet Derived Growth Factor (PDGF) is a potent mitogen for a wide range of cell types including fibroblasts, smooth muscle and connective tissue. Recombinant human platelet derived growth factor (R-Pdf/Gbb) has biologic activity similar to endogenous platelet derived growth factor (PDGF). Biologic activity of PDGF includes encouraging chemotaxis and proliferation of cells responsible for wound repair and it augments production of granulation tissue. The growth factor rhPDGF is found effective in patients having diabetic foot ulcer grade III and IV. The nature of wounds in the third degree burns is similar so far as healing process is concerned. The purpose of this study is to test the hypotheses that the application of R-Pdf/Gbb 0.01% gel on the third degree thermal and electrical burns will heal these wounds within 3 months and there will be improvement in general condition of the patients without any complications.

Conditions

  • Burns
  • Electric Burns

Interventions

  • R-Pdf/Gbb 0.01% gelDrug

    rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete healing of the third degree burn wound.Time frame: 3 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Saint. Barnabas Medical Center, The Burn Center

    Livingston, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.